What's new? Log in Free sign up

Rani Therapeutics (RANI)

Company Profile

Company profile

Ticker

RANI

Exchange

Website

www.ranitherapeutics.com

CEO

Mr. Talat Imran

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Rani Therapeutics, LLC ...

RANI stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Quarterly report

14 Nov 24

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

Prospectus supplement for primary offering

Changes in Registrant's Certifying Accountant

Prospectus supplement for primary offering

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Dennis A Ausiello

Lisa Ann Rometty

LAUREEN DEBUONO

Andrew Farquharson

Maulik Nanavaty

ARMISTICE CAPITAL, LLC

Financial summary

Financial statements Chart RANI financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.78 mm	4.78 mm	4.78 mm	4.78 mm	4.78 mm	4.78 mm
Cash burn (monthly)	866.67 k	272.92 k	3.93 mm	4.85 mm	4.24 mm	4.08 mm
Cash used (since last report)	2.44 mm	769.15 k	11.08 mm	13.67 mm	11.95 mm	11.49 mm
Cash remaining	2.33 mm	4.01 mm	-6.31 mm	-8.90 mm	-7.17 mm	-6.71 mm
Runway (months of cash)	2.7	14.7	-1.6	-1.8	-1.7	-1.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

RANI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	37	36	+2.8%
Opened positions	8	26	-69.2%
Closed positions	7	2	+250.0%
Increased positions	9	0	NEW
Reduced positions	4	1	+300.0%

13F shares	Current	Prev Q	Change
Total value	11.14 bn	7.46 bn	+49.4%
Total shares	29.33 mm	28.87 mm	+1.6%
Total puts	4.20 k	0.00	NEW
Total calls	32.80 k	30.90 k	+6.1%
Total put/call ratio	0.1	–	–

Largest owners	Shares	Value	Change
South Lake One	12.13 mm	$24.38 mm	0.0%
Quiroga Moreno Isidoro	11.73 mm	$129.05 mm	0.0%
InCube Ventures II	2.57 mm	$41.96 mm	0.0%
Vanguard	709.83 k	$2.70 bn	+3.6%
Nan Fung	493.58 k	$1.88 bn	0.0%
GOOG Alphabet	448.49 k	$1.70 bn	0.0%
United Services Automobile Association	312.10 k	$1.19 bn	NEW
Geode Capital Management	150.73 k	$572.92 mm	+15.1%
SF Stifel Financial	134.62 k	$511.56 mm	+1.7%
BAC Bank of America	91.85 k	$349.02 mm	NEW

Largest transactions	Shares	Bought/sold	Change
United Services Automobile Association	312.10 k	+312.10 k	NEW
BAC Bank of America	91.85 k	+91.85 k	NEW
King Luther Capital Management	56.13 k	+56.13 k	NEW
Renaissance Technologies	21.70 k	-48.60 k	-69.1%
Alpha Square Group S	0.00	-33.40 k	EXIT
Vanguard	709.83 k	+24.53 k	+3.6%
HRT Financial	0.00	-22.59 k	EXIT
Marshall Wace	21.25 k	+21.25 k	NEW
Bridgeway Capital Management	71.50 k	+20.00 k	+38.8%
Geode Capital Management	150.73 k	+19.83 k	+15.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RANI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 24	Jean Luc Butel	Stock Option Class A Common Stock	Grant	Acquire A	No	No	9.44	18,875	178.18 k	135,896
16 Dec 24	Jean Luc Butel	Stock Option Class A Common Stock	Sale back to company	Dispose D	No	No	2.84	18,875	53.61 k	0
16 Dec 24	Jean Luc Butel	Stock Option Class A Common Stock	Grant	Acquire A	No	No	4.11	101,276	416.24 k	101,276
16 Dec 24	Jean Luc Butel	Stock Option Class A Common Stock	Sale back to company	Dispose D	No	No	2.84	101,276	287.62 k	0
16 Dec 24	Mir A Imran	Stock Option Class A Common Stock	Grant	Acquire A	No	No	4.11	101,276	416.24 k	101,276
16 Dec 24	Mir A Imran	Stock Option Class A Common Stock	Sale back to company	Dispose D	No	No	2.84	101,276	287.62 k	0
16 Dec 24	Ausiello Dennis A	Stock Option Class A Common Stock	Grant	Acquire A	No	No	9.44	15,423	145.59 k	79,317
16 Dec 24	Ausiello Dennis A	Stock Option Class A Common Stock	Sale back to company	Dispose D	No	No	2.84	15,423	43.80 k	0
16 Dec 24	Ausiello Dennis A	Stock Option Class A Common Stock	Grant	Acquire A	No	No	4.11	101,276	416.24 k	101,276
16 Dec 24	Ausiello Dennis A	Stock Option Class A Common Stock	Sale back to company	Dispose D	No	No	2.84	101,276	287.62 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $9 price target.

Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 33.33 percent increase over losses of $(0.36) per

Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_10222024_RANI_Vandermosten.pdf

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target

Rani Therapeutics Announces New Preclinical Data Supporting Transenteric Delivery Of GLP-1 Incretin Triagonist With Rapid Weight Loss And Bioavailability Comparable To Injection

Press releases

From Benzinga Pro

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Peraso Inc. (NASDAQ:PRSO) specializes in advanced millimeter wave (mmWave) technology, a critical component of modern wireless communication systems. Their cutting-edge steerable beam technology, powered by a phased

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New

"Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology" more stocks inside….

Millimeter Wave (mmWave) technology, operating in the 24 GHz to 300 GHz frequency range, is set to revolutionize everyday life, with Peraso Inc. (NASDAQ:PRSO) at the forefront as the key innovator driving these

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.